ArticleBDJ open2026
Drug-associated tongue discoloration: a comprehensive assessment of USFDA adverse event reporting system using disproportionality analysis.
Article in BDJ open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDrug-induced tongue discoloration can impact quality of life but remain under-recognized. While several antimicrobials are implicated, comprehensive signals across many drug classes remain poorly characterized.
methodsReports of tongue discoloration, strawberry tongue, and black hairy tongue were extracted from the USFDA Adverse Event Reporting System from 2004 to 2024. Disproportionality analysis was conducted using reporting odds ratio, proportional reporting ratio, Bayesian confidence propagation neural network, and multi-item gamma Poisson shrinker to detect associations between implicated drugs and tongue conditions.
resultsA total of 2352 reports were analyzed. Drugs consistently associated with tongue discoloration by both frequentist and Bayesian analyses included clarithromycin, metronidazole, linezolid, amoxicillin, and fluticasone. Flucloxacillin and immunoglobulin G emerged as risks for strawberry tongue. Meclizine showed a signal for black hairy tongue across methods, whereas other drugs appeared risk factors using only frequentist tests. Demographic patterns varied by condition.
conclusionThis comprehensive signal detection revealed several high-priority drug-tongue condition associations using large-scale pharmacovigilance data. Findings carry implications for guiding clinical practice through enhancing adverse effect monitoring for high-risk medications. Priority signals merit validation through further research to optimize benefit-risk assessment and reduce preventable tongue disorders.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.